Jonathan Chang
Stock Analyst at Leerink Partners
(3.72)
# 1,965
Out of 4,382 analysts
552
Total ratings
36.1%
Success rate
4.8%
Average return
Main Sectors:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Reiterated: Hold | n/a | $9.47 | - | 49 | Jun 2, 2026 | |
| MOLN Molecular Partners AG | Reiterated: Buy | n/a | $4.10 | - | 7 | Jun 2, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $67 → $147 | $149.23 | -1.49% | 40 | Apr 13, 2026 | |
| NBTX Nanobiotix | Maintained: Buy | $24 → $37 | $35.45 | +4.37% | 17 | Apr 1, 2026 | |
| IMTX Immatics | Reiterated: Buy | $17 | $9.79 | +73.65% | 44 | Mar 6, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $31 | $18.87 | +64.28% | 1 | Feb 3, 2026 | |
| NVCR NovoCure | Reiterated: Buy | $33 → $24 | $17.16 | +39.86% | 19 | Jan 13, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $20 | $8.74 | +128.83% | 51 | Jan 13, 2026 | |
| ZLAB Zai Lab | Reiterated: Buy | $74 | $16.62 | +345.25% | 51 | Oct 21, 2025 | |
| GMAB Genmab | Reiterated: Buy | $34 → $39 | $25.15 | +55.07% | 45 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $6 | $9.08 | -33.92% | 36 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $5 | $3.92 | +27.71% | 38 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $0.11 → $0.09 | $0.0339 | +165.49% | 38 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $4.19 | +472.79% | 30 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $28.29 | +112.09% | 13 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $11.77 | +129.40% | 32 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.0127 | n/a | 23 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $891.32 | n/a | 1 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $59.18 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 → $2 | $0.0003 | n/a | 15 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.96 | n/a | 1 | Jun 1, 2022 |
Replimune Group
Jun 2, 2026
Reiterated: Hold
Price Target: n/a
Current: $9.47
Upside: -
Molecular Partners AG
Jun 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.10
Upside: -
Revolution Medicines
Apr 13, 2026
Reiterated: Buy
Price Target: $67 → $147
Current: $149.23
Upside: -1.49%
Nanobiotix
Apr 1, 2026
Maintained: Buy
Price Target: $24 → $37
Current: $35.45
Upside: +4.37%
Immatics
Mar 6, 2026
Reiterated: Buy
Price Target: $17
Current: $9.79
Upside: +73.65%
Aktis Oncology
Feb 3, 2026
Initiated Coverage: Buy
Price Target: $31
Current: $18.87
Upside: +64.28%
NovoCure
Jan 13, 2026
Reiterated: Buy
Price Target: $33 → $24
Current: $17.16
Upside: +39.86%
Kura Oncology
Jan 13, 2026
Reiterated: Buy
Price Target: $20
Current: $8.74
Upside: +128.83%
Zai Lab
Oct 21, 2025
Reiterated: Buy
Price Target: $74
Current: $16.62
Upside: +345.25%
Genmab
Oct 13, 2025
Reiterated: Buy
Price Target: $34 → $39
Current: $25.15
Upside: +55.07%
Oct 10, 2025
Maintained: Hold
Price Target: $8 → $6
Current: $9.08
Upside: -33.92%
Aug 18, 2025
Maintained: Buy
Price Target: $8 → $5
Current: $3.92
Upside: +27.71%
Aug 13, 2025
Maintained: Hold
Price Target: $0.11 → $0.09
Current: $0.0339
Upside: +165.49%
Aug 11, 2025
Reiterated: Buy
Price Target: $24
Current: $4.19
Upside: +472.79%
Aug 11, 2025
Maintained: Buy
Price Target: $60
Current: $28.29
Upside: +112.09%
Aug 7, 2025
Reiterated: Buy
Price Target: $27
Current: $11.77
Upside: +129.40%
Nov 12, 2024
Reiterated: Buy
Price Target: $2
Current: $0.0127
Upside: n/a
Jun 30, 2023
Maintained: Buy
Price Target: n/a
Current: $891.32
Upside: n/a
Jan 11, 2023
Rated: Buy
Price Target: n/a
Current: $59.18
Upside: n/a
Nov 14, 2022
Downgraded: Hold
Price Target: $18 → $2
Current: $0.0003
Upside: n/a
Jun 1, 2022
Maintained: Buy
Price Target: n/a
Current: $4.96
Upside: n/a